[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Gold et al., 2010 - Google Patents

Aptamer-based multiplexed proteomic technology for biomarker discovery

Gold et al., 2010

View PDF
Document ID
4608637795569123588
Author
Gold L
Ayers D
Bertino J
Bock C
Bock A
Brody E
Carter J
Cunningham V
Dalby A
Eaton B
Fitzwater T
Flather D
Forbes A
Foreman T
Fowler C
Gawande B
Goss M
Gunn M
Gupta S
Halladay D
Heil J
Heilig J
Hicke B
Husar G
Janjic N
Jarvis T
Jennings S
Katilius E
Keeney T
Kim N
Kaske T
Koch T
Kraemer S
Kroiss L
Le N
Levine D
Lindsey W
Lollo B
Mayfield W
Mehan M
Mehler R
Nelson M
Nelson S
Nieuwlandt D
Nikrad M
Ochsner U
Ostroff R
Otis M
Parker T
Pietrasiewicz S
Resnicow D
Rohloff J
Sanders G
Sattin S
Schneider D
Singer B
Stanton M
Sterkel A
Stewart A
Stratford S
Vaught J
Vrkljan M
Walker J
Watrobka M
Waugh S
Weiss A
Wilcox S
Wolfson A
Wolk S
Zhang C
Zichi D
Publication year
Publication venue
Nature Precedings

External Links

Snippet

Interrogation of the human proteome in a highly multiplexed and efficient manner remains a coveted and challenging goal in biology. We present a new aptamer-based proteomic technology for biomarker discovery capable of simultaneously measuring thousands of …
Continue reading at www.nature.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/543—Immunoassay; Biospecific binding assay with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/5308—Immunoassay; Biospecific binding assay for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Similar Documents

Publication Publication Date Title
Gold et al. Aptamer-based multiplexed proteomic technology for biomarker discovery
Ostroff et al. The stability of the circulating human proteome to variations in sample collection and handling procedures measured with an aptamer-based proteomics array
JP6448584B2 (en) Methods and compositions for diagnosis and prognosis of kidney injury and renal failure
US20200166523A1 (en) Cardiovascular Risk Event Prediction and Uses Thereof
JP5404620B2 (en) Multiplexed analysis of test samples
US20110251099A1 (en) SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
Wilson et al. Antibody arrays in biomarker discovery
WO2016069461A1 (en) A parkinson's disease diagnostic biomarker panel
US20210398682A1 (en) Methods for Evaluation of Gestational Progress and Preterm Abortion for Clinical Intervention and Applications Thereof
US20150031562A1 (en) Biomarkers for multiple sclerosis and methods of use thereof
JP2016513253A (en) Methods for measuring acute respiratory distress syndrome (ARDS) related biomarkers, methods for monitoring the progression and treatment of ARDS in patients
WO2015193427A1 (en) Determination and analysis of biomarkers in clinical samples
Ydens et al. The next generation of biomarker research in spinal cord injury
Alghamdi et al. Advances in the diagnosis of autoimmune diseases based on citrullinated peptides/proteins
Christians et al. The role of proteomics in the study of kidney diseases and in the development of diagnostic tools
US20140011879A1 (en) Serum markers for identification of cutaneous systemic sclerosis subjects
WO2005113831A2 (en) Biomarkers for multiple sclerosis and methods of use thereof
Wang et al. Arraying autoantibodies in SLE–lessons learned
Vasunilashorn et al. Application of multiple omics to understand postoperative delirium pathophysiology in humans
Huang Cytokine antibody arrays: a promising tool to identify molecular targets for drug discovery
EP3961217A1 (en) Method for diagnosing endometriosis, disease state monitoring method, and kit
Umstead et al. The kinetics of cardiopulmonary bypass: a dual‐platform proteomics study of plasma biomarkers in pediatric patients undergoing cardiopulmonary bypass
Gong et al. A Facile Strategy for Multiplex Protein Detection by a Fluorescent Microsphere-Based Digital Immunoassay
Wang et al. Methods and clinical biomarker discovery for targeted proteomics using Olink technology
US20240192227A1 (en) Methods of diagnosing and predicting renal decline